Cell Reports is a prestigious open-access journal published by CELL PRESS that has firmly established itself as a leading voice in the fields of Biochemistry, Genetics, and Molecular Biology. Since its inception in 2012, the journal has provided an innovative platform for rapid dissemination of cutting-edge research, ensuring that high-quality findings are accessible to a global audience. With an impressive impact factor and ranking within the top 10% in its category, as reflected by its Q1 ranking in Scopus, Cell Reports serves a vital role in advancing scientific knowledge and fostering collaboration among researchers. The journal's commitment to the open-access model not only enhances visibility but also encourages the sharing of critical advancements in molecular biology. Situated in the Netherlands, its contributions are recognized worldwide, making Cell Reports an indispensable resource for scientists aiming to stay at the forefront of their fields and facilitate breakthroughs that may shape the future of biomedicine.

FEBS Journal is a prestigious, peer-reviewed publication dedicated to advancing the field of biochemistry, cell biology, and molecular biology. Published by WILEY in the United Kingdom, this journal boasts an impressive impact factor and ranks in the top quartile (Q1) across multiple relevant categories, including Biochemistry, Cell Biology, and Molecular Biology, reflecting its significant contribution to scientific research. With an ISSN of 1742-464X and an E-ISSN of 1742-4658, the FEBS Journal publishes original research and comprehensive reviews that push the boundaries of knowledge and innovation in the biosciences. As a vital resource for researchers, professionals, and students alike, the journal offers Open Access options, ensuring that cutting-edge discoveries are accessible to a broad audience. With a publication history converging from 2005 to the present and a robust emphasis on high-quality scholarly work, the FEBS Journal remains an essential platform for the dissemination of significant findings and advancements in the life sciences.

IUBMB LIFE is a prestigious, peer-reviewed journal published by WILEY, dedicated to advancing the fields of biochemistry, molecular biology, and cell biology. With an impressive impact factor and consistently ranked in the Q1 and Q2 categories across multiple relevant disciplines—including Biochemistry, Genetics, and Clinical Biochemistry—this journal has established itself as a leading platform for disseminating innovative research and critical reviews that propel scientific discovery. The journal spans a converged publication period from 1999 to 2024, providing comprehensive insights into the dynamic landscape of biochemical research. Researchers, professionals, and students alike are invited to explore its Open Access options, ensuring that groundbreaking studies are accessible to a global audience. As it continues to shape the future of life sciences, IUBMB LIFE remains a vital resource for those seeking to enrich their understanding and contribute to these rapidly evolving fields.

FEBS LETTERS, published by Wiley, is a prestigious journal that has firmly established its place in the fields of biochemistry, biophysics, genetics, molecular biology, cell biology, and structural biology. With an esteemed history dating back to 1968, this journal continues to be a vital resource for researchers and professionals involved in the biological sciences. It boasts impressive quartile rankings, including Q1 statuses in several categories such as Biochemistry and Genetics, reflecting its high impact factor and significant contribution to scientific discourse. FEBS LETTERS provides a platform for innovative findings and critical reviews, fostering the exchange of knowledge and ideas within the scientific community. Although it operates under a subscription model, the journal ensures broad dissemination of groundbreaking research through its rigorous peer-review process. The vibrant discussions encouraged by articles published in FEBS LETTERS aim to inspire current and future generations of scientists to push the boundaries of biological understanding, making it an indispensable resource for anyone dedicated to advancing their knowledge in these dynamic fields.

FEBS Open Bio is a leading open-access journal published by Wiley, dedicated to advancing our understanding of biochemistry, genetics, and molecular biology. Since its inception in 2011, this journal has provided a robust platform for researchers to share their findings with a wider audience, ensuring the dissemination of high-quality scientific knowledge. With an impact factor reflecting its stature in its field, FEBS Open Bio is ranked #77 out of 221 in general biochemistry, genetics, and molecular biology, placing it in the 65th percentile among its peers. This journal serves as an essential resource for professionals, researchers, and students alike, fostering collaboration and innovation within the scientific community. The commitment to open access not only enhances visibility but also promotes transparency in research, making it a vital contributor to the ongoing dialogue in biochemical and molecular biological sciences. For those looking to stay at the forefront of research developments, FEBS Open Bio is a key publication addressing the latest trends and discoveries in the field.

Purinergic Signalling, published by Springer, is a pivotal academic journal dedicated to the exploration of purinergic signaling pathways and their implications in various biological processes. Since its inception in 2004, the journal has made significant contributions to the fields of Cell Biology, Cellular and Molecular Neuroscience, and Molecular Biology, consistently ranking in the Q3 category in recent assessments. With a strong focus on the molecular mechanisms of purines and their roles in physiology and pathology, Purinergic Signalling serves as an essential resource for researchers and professionals seeking to understand the complexity of cellular communication. Although it does not offer open access, the journal ensures a broad dissemination of high-quality research findings, making it a vital tool for academic advancement in the fields of neuroscience and molecular biology. Its commitment to scholarly excellence is reflected in its Scopus rankings, where it is competitively positioned within its categories. As we approach its 20th anniversary in 2024, Purinergic Signalling continues to inspire and inform cutting-edge research in the dynamic landscape of life sciences.

International Journal of Biological Sciences (ISSN: 1449-2288, E-ISSN: 1449-2288) is a premier open-access journal published by IVYSPRING INTERNATIONAL PUBLISHING since 2005, located in Australia. With a commitment to advancing knowledge in the life sciences, this journal covers a wide spectrum of disciplines, including Applied Microbiology and Biotechnology, Cell Biology, Developmental Biology, Ecology, Evolution, Behavior and Systematics, and Molecular Biology, earning a distinguished Q1 ranking in these fields as of 2023. It stands out with exceptional Scopus rankings, placing in the top ranks across multiple categories, such as the 98th percentile in Ecology, Evolution, Behavior and Systematics and the 94th percentile in Applied Microbiology and Biotechnology. The journal fosters an open access philosophy, ensuring that research findings are readily available to the scientific community and the public, and invites original research articles, reviews, and commentaries. With its mission to disseminate high-quality research, the International Journal of Biological Sciences serves as an essential resource for researchers, professionals, and students seeking to deepen their understanding and drive innovation in biological sciences.

FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.

Animal Cells and Systems, published by TAYLOR & FRANCIS LTD, is a prominent open-access journal that has been disseminating high-quality research since 2017. With an ISSN of 1976-8354 and an E-ISSN of 2151-2485, this journal is dedicated to advancing the understanding of animal cellular biology and the intricate systems that govern organismal functions. Recognized for its rigorous peer-review process, it holds an esteemed position in the academic community, boasting a Q1 ranking in Animal Science and Zoology and a Q2 ranking in Biochemistry, Genetics and Molecular Biology for 2023. The journal is indexed in Scopus, ranked #79/490 in Animal Science and Zoology and #85/221 in General Biochemistry, Genetics, and Molecular Biology, affirming its impact and relevance in these fields. With a commitment to providing researchers, professionals, and students with vital insights and cutting-edge research, Animal Cells and Systems is an essential resource for those looking to explore the complex landscapes of animal biology.

Welcome to the Korean Journal of Physiology & Pharmacology, a pivotal academic platform dedicated to advancing the disciplines of physiology and pharmacology. Published by the esteemed Korean Journal of Physiology & Pharmacology, this journal has been disseminating valuable research findings since its inception in 1997 and continues to be a critical resource for researchers, professionals, and students in South Korea and beyond. With an ISSN of 1226-4512 and E-ISSN of 2093-3827, it offers insights into various aspects of drug action and physiological mechanisms. Although this journal currently does not subscribe to Open Access, it plays a vital role in bridging the gap between experimental and clinical studies, receiving commendations for its quality. In the 2023 Scopus rankings, it is notably positioned in the Q3 quartile for Pharmacology and Q4 for Physiology, reflecting its commitment to excellence. As the journal converges towards its comprehensive coverage in 2024, it remains a cornerstone for those looking to engage deeply with critical developments in these fields.